- Home
- GPOR vs AKRO Comparison
GPOR vs AKRO Comparison
Compare GPOR & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPOR
- AKRO
- Stock Information
- Founded
- GPOR 1997
- AKRO 2017
- Country
- GPOR United States
- AKRO United States
- Employees
- GPOR N/A
- AKRO N/A
- Industry
- GPOR Oil & Gas Production
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- GPOR Energy
- AKRO Health Care
- Exchange
- GPOR Nasdaq
- AKRO Nasdaq
- Market Cap
- GPOR 3.3B
- AKRO 3.9B
- IPO Year
- GPOR N/A
- AKRO 2019
- Fundamental
- Price
- GPOR $169.39
- AKRO $50.49
- Analyst Decision
- GPOR Buy
- AKRO Strong Buy
- Analyst Count
- GPOR 8
- AKRO 6
- Target Price
- GPOR $214.50
- AKRO $82.50
- AVG Volume (30 Days)
- GPOR 317.7K
- AKRO 1.2M
- Earning Date
- GPOR 08-05-2025
- AKRO 08-08-2025
- Dividend Yield
- GPOR N/A
- AKRO N/A
- EPS Growth
- GPOR N/A
- AKRO N/A
- EPS
- GPOR N/A
- AKRO N/A
- Revenue
- GPOR $1,014,317,000.00
- AKRO N/A
- Revenue This Year
- GPOR $56.18
- AKRO N/A
- Revenue Next Year
- GPOR $13.45
- AKRO N/A
- P/E Ratio
- GPOR N/A
- AKRO N/A
- Revenue Growth
- GPOR 11.01
- AKRO N/A
- 52 Week Low
- GPOR $130.02
- AKRO $21.34
- 52 Week High
- GPOR $210.32
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- GPOR 38.56
- AKRO 43.24
- Support Level
- GPOR $165.59
- AKRO $50.60
- Resistance Level
- GPOR $174.78
- AKRO $52.55
- Average True Range (ATR)
- GPOR 6.25
- AKRO 1.81
- MACD
- GPOR -1.43
- AKRO -0.37
- Stochastic Oscillator
- GPOR 26.98
- AKRO 11.25
About GPOR Gulfport Energy Corporation
Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition, and production of natural gas, crude oil, and natural gas liquids, with assets predominantly located in the Appalachia and Anadarko basins in the United States. Its principal properties are located in eastern Ohio, targeting the Utica and Marcellus, and in central Oklahoma, targeting the SCOOP Woodford and Springer formations.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.